Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Buyout framework

<< Previous

Bullboard Posts

Next >>

Comment by Triggertwoon Oct 26, 2020 9:58am

115 Views

Post# 31780759

RE:RE:RE:RE:Buyout framework

BITW you obviously don't know what your talking about. I will ignore you in the future.

[Prominent examples include Pfizer’s Viagra (sildenafil) for erectile dysfunction and Celgene’s Thalomid (thalidomide) for the treatment of erythema nodosum leprosum (ENL) and multiple myeloma.]

https://www.biopharma-excellence.com/news/2019/2/25/drug-repurposing-how-to-protect-your-asset-by-an-integrated-regulatory-strategy

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec